Companion Animal Pharmaceuticals Market by Animal Type (Dogs, Cats, Horses), Route of Administration (Oral, Injectable, Topical), Indication (Antibiotics, Parasiticides), Distribution Channel (Veterinary Hospitals & Clinics) & Region - Global Forecasts to 2027
The global companion animal pharmaceuticals market is projected to reach USD 19.6 billion by 2027 from USD 14.4 billion in 2022, at a CAGR of 6.3% during the forecast period. The Rising prevalence of zoonotic diseases, Rising demand for pet insurance due to growing animal health expenditure, Increasing R&D investments for animal healthcare, Initiatives by various government agencies and animal associations, High pet ownership rates worldwide are some of the factors driving the growth of these markets. However, Rising pet care costs, Limited number of new product developments, High cost of vaccines and complexities associated with storage, Growing resistance to antimicrobials and antibiotics are restraining the growth of this market to a certain extent.
“The dermatologic diseases segment is projected to grow at the highest CAGR in the companion animal pharmaceuticals market.”
The dermatologic diseases segment is projected to grow at the highest CAGR during the forecast period. The rising need for advanced orthopedic drugs, increasing prevalence of arthritis, and growing pet population in developed and developing countries are some of the key factors driving the growth of this segment.
“In the forecast period, the dogs segment holds the largest share in the animal type segment.”
The dogs segment accounted for the largest market share in 2021. The large share of this segment is attributed to the increasing dog population and rising ownership rate in both developed and developing countries , rising canine healthcare expenditure, increasing prevalence of zoonotic diseases and other skin allergies in dogs, and the rising number of pet insurers across the globe.
“In the forecast period, by distribution channel segment, veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market”
During the forecast period, the veterinary hospitals segment is expected to grow at the highest CAGR. The higher adoption of animal parasiticides, analgesic, antimicrobials and antibiotics in hospital settings, rising cases of infectious diseases, increasing number of veterinary hospitals, growing ownership rate of companion animals, and rising veterinary expenditure are some of the key factors driving the growth of this segment.
“By Region, North America holds the largest share in the companion animal pharmaceuticals market, in the forecast period”
By Region, In 2021, North America accounted for the largest share of the companion animal pharmaceuticals market in the forecast period, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the high adoption rate of companion animals such as dogs and cats, well-established base of animal health industries, rising animal adoption centers, rising cases of parasitic infections, the large number of hospitals and clinics, growing expenditure on animal health in the region and , growing pool of veterinarians.
A breakdown of the primary participants for the companion animal pharmaceuticals market referred to for this report is provided below:
Research Coverage:
This research report categorizes the companion animal pharmaceuticals market by indication, by route of administration, by animal type, by distribution channel and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the companion animal pharmaceuticals market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the companion animal pharmaceuticals market. Competitive analysis of upcoming startups in the C4ISR market ecosystem is covered in this report.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall C4ISR market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
“The dermatologic diseases segment is projected to grow at the highest CAGR in the companion animal pharmaceuticals market.”
The dermatologic diseases segment is projected to grow at the highest CAGR during the forecast period. The rising need for advanced orthopedic drugs, increasing prevalence of arthritis, and growing pet population in developed and developing countries are some of the key factors driving the growth of this segment.
“In the forecast period, the dogs segment holds the largest share in the animal type segment.”
The dogs segment accounted for the largest market share in 2021. The large share of this segment is attributed to the increasing dog population and rising ownership rate in both developed and developing countries , rising canine healthcare expenditure, increasing prevalence of zoonotic diseases and other skin allergies in dogs, and the rising number of pet insurers across the globe.
“In the forecast period, by distribution channel segment, veterinary hospitals is expected to grow at the highest CAGR in the companion animal pharmaceuticals market”
During the forecast period, the veterinary hospitals segment is expected to grow at the highest CAGR. The higher adoption of animal parasiticides, analgesic, antimicrobials and antibiotics in hospital settings, rising cases of infectious diseases, increasing number of veterinary hospitals, growing ownership rate of companion animals, and rising veterinary expenditure are some of the key factors driving the growth of this segment.
“By Region, North America holds the largest share in the companion animal pharmaceuticals market, in the forecast period”
By Region, In 2021, North America accounted for the largest share of the companion animal pharmaceuticals market in the forecast period, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the high adoption rate of companion animals such as dogs and cats, well-established base of animal health industries, rising animal adoption centers, rising cases of parasitic infections, the large number of hospitals and clinics, growing expenditure on animal health in the region and , growing pool of veterinarians.
A breakdown of the primary participants for the companion animal pharmaceuticals market referred to for this report is provided below:
- By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
- By Designation: C-level–35%, Director Level–25%, and Others–40%
- By Region: North America–40%, Asia- Pacific–30%, Europe–20%, Middle East & Africa–5%, Latin America- 5%
Research Coverage:
This research report categorizes the companion animal pharmaceuticals market by indication, by route of administration, by animal type, by distribution channel and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the companion animal pharmaceuticals market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the companion animal pharmaceuticals market. Competitive analysis of upcoming startups in the C4ISR market ecosystem is covered in this report.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall C4ISR market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion animal pharmaceuticals market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global companion animal pharmaceuticals market
- Market Development: Comprehensive information on the lucrative emerging regions by indication, animal type, distribution channels, and region
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion animal pharmaceuticals market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products of leading players in the global companion animal pharmaceuticals market
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.2.2 MARKETS COVERED
FIGURE 1 COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED
1.3 CURRENCY CONSIDERED
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 REFINEMENTS IN SEGMENTS OF GLOBAL MARKET
1.6.2 UPDATED FINANCIAL INFORMATION/PRODUCT PORTFOLIOS OF PLAYERS
1.6.3 UPDATED MARKET DEVELOPMENTS OF PROFILED PLAYERS
1.6.4 ADDITION OF RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primaries
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: ZOETIS INC.
FIGURE 6 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY-SIDE ANALYSIS
FIGURE 7 MARKET ANALYSIS APPROACH
FIGURE 8 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET APPROACH
FIGURE 9 TOP-DOWN APPROACH
FIGURE 10 CAGR PROJECTIONS
FIGURE 11 COMPANION ANIMAL PHARMACEUTICALS MARKET (2022–2027): IMPACT ANALYSIS ON DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 DATA TRIANGULATION APPROACH
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 IMPACT OF RECESSION
3 EXECUTIVE SUMMARY
FIGURE 13 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 14 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD MILLION)
FIGURE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2022 VS. 2027 (USD MILLION)
FIGURE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHICAL SNAPSHOT
4 PREMIUM INSIGHTS
4.1 COMPANION ANIMAL PHARMACEUTICALS MARKET OVERVIEW
FIGURE 18 INCREASING PREVALENCE OF ZOONOTIC DISEASES AND RISING PET OWNERSHIP RATES WORLDWIDE TO DRIVE MARKET
4.2 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION AND COUNTRY (2021)
FIGURE 19 INFECTIOUS DISEASES SEGMENT IN GERMANY ACCOUNTED FOR LARGEST SHARE IN 2021
4.3 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 CHINA & INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (2022–2027)
FIGURE 21 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD
4.5 COMPANION ANIMAL PHARMACEUTICALS MARKET: DEVELOPED VS. EMERGING MARKETS
FIGURE 22 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 COMPANION ANIMAL PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 MARKET DRIVERS
5.2.1.1 Rising prevalence of zoonotic diseases
TABLE 2 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2013–2019)
5.2.1.2 Rising demand for pet insurance due to growing animal health expenditure
TABLE 3 US: AVERAGE PREMIUM RATES (2019–2021)
FIGURE 24 CANADA: AVERAGE ANNUAL PREMIUMS (2017–2021)
TABLE 4 NORTH AMERICA: PET HEALTH INSURANCE MARKET, 2012–2021 (USD MILLION)
5.2.1.3 Increasing R&D investments for animal healthcare
5.2.1.4 Rising awareness initiatives by government agencies and animal welfare organizations
5.2.1.5 High pet ownership rates worldwide
TABLE 5 PET POPULATION, BY ANIMAL, 2014–2020 (MILLION)
TABLE 6 MARKET DRIVERS: IMPACT ANALYSIS
5.2.2 MARKET RESTRAINTS
5.2.2.1 Rising pet care costs
FIGURE 25 US: PET INDUSTRY EXPENDITURE, 2010–2020
5.2.2.2 Limited number of novel pharmaceuticals for veterinary care
5.2.2.3 High cost of vaccines and complexities associated with storage
5.2.2.4 Growing resistance to antimicrobials and antibiotics
TABLE 7 MARKET RESTRAINTS: IMPACT ANALYSIS
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Lucrative growth opportunities in emerging markets
5.2.3.2 Growing prevalence of chronic animal diseases
5.2.3.3 Rising technological advancements in vaccine manufacturing
TABLE 8 MARKET OPPORTUNITIES: IMPACT ANALYSIS
5.2.4 MARKET CHALLENGES
5.2.4.1 Stringent regulatory approval process for pharmaceuticals
5.2.4.2 Limited awareness of vaccine coverage
5.2.4.3 Misdiagnosis due to diversity of parasites
5.2.4.4 Low animal healthcare expenditure in emerging markets
TABLE 9 MARKET CHALLENGES: IMPACT ANALYSIS
6 INDUSTRY INSIGHTS
6.1 INTRODUCTION
6.2 INDUSTRY TRENDS
6.2.1 RISING ACQUISITIONS OF SMALLER COMPANIES BY GLOBAL PLAYERS
TABLE 10 COMPANION ANIMAL PHARMACEUTICALS MARKET: MAJOR ACQUISITIONS (2017–2022)
6.2.2 INCREASING PRODUCT INNOVATIONS FOR ANIMAL HEALTHCARE
TABLE 11 INNOVATIVE COMPANION ANIMAL PHARMACEUTICAL TRENDS
6.2.3 EXPANDING VETERINARY BUSINESSES WORLDWIDE
6.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 12 PORTER’S FIVE FORCES ANALYSIS
6.3.1 THREAT OF NEW ENTRANTS
6.3.2 THREAT OF SUBSTITUTES
6.3.3 BARGAINING POWER OF SUPPLIERS
6.3.4 BARGAINING POWER OF BUYERS
6.3.5 INTENSITY OF COMPETITIVE RIVALRY
6.4 REGULATORY ANALYSIS
FIGURE 26 COMPANION ANIMAL PHARMACEUTICAL MARKET: DEVELOPMENT AND APPROVAL PROCESS FOR PRODUCTS
TABLE 13 US: RECENT DEVELOPMENTS IN REGULATIONS FOR VETERINARY DRUGS
FIGURE 27 COMPANION ANIMAL PHARMACEUTICAL MARKET: PRODUCT APPROVAL PROCESS IN EUROPE
6.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.4.1.1 US
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.4.1.2 Europe
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.4.1.3 Rest of the World
TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.5 VALUE CHAIN ANALYSIS
FIGURE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS
6.6 SUPPLY CHAIN ANALYSIS
FIGURE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS
6.7 ECOSYSTEM ANALYSIS
6.7.1 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS
FIGURE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS
6.8 PATENT ANALYSIS
6.8.1 COMPANION ANIMAL PHARMACEUTICALS MARKET: PATENT ANALYSIS TRENDS
FIGURE 31 PATENT PUBLICATION TRENDS (JANUARY 2013–DECEMBER 2022)
6.8.2 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICALS
FIGURE 32 COMPANION ANIMAL PHARMACEUTICALS MARKET: TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR PATENTS (2017–2022)
6.8.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR COMPANION ANIMAL PHARMACEUTICALS
FIGURE 33 COMPANION ANIMAL PHARMACEUTICAL MARKET: TOP APPLICANT COUNTRIES FOR PATENTS (2017–2022)
6.9 PRICING ANALYSIS
TABLE 17 AVERAGE SELLING PRICES OF COMPANION ANIMAL PHARMACEUTICALS BY APPLICATION (USD)
6.10 KEY CONFERENCES AND EVENTS FROM 2023 TO 2024
TABLE 18 COMPANION ANIMAL PHARMACEUTICALS MARKET: CONFERENCES AND EVENTS
6.11 KEY STAKEHOLDERS & BUYING CRITERIA
6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 34 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS
TABLE 19 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS
FIGURE 35 BUYING CRITERIA
TABLE 20 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
6.12 TRADE ANALYSIS
7 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION
7.1 INTRODUCTION
TABLE 21 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
7.2 INFECTIOUS DISEASES
TABLE 22 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 23 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 PARASITICIDES
7.2.1.1 Growing regulatory guidelines to control parasite-related diseases to fuel market
TABLE 24 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.2 VACCINES
7.2.2.1 Growing awareness among pet owners for canine & feline vaccines to drive market
TABLE 25 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 ANTIBIOTICS AND ANTIMICROBIALS
7.2.3.1 Effective prevention for clinical and subclinical diseases in companion animals to fuel uptake
TABLE 26 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS AND ANTIMICROBIALS, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.4 OTHERS
TABLE 27 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 DERMATOLOGIC DISEASES
7.3.1 RISING CASES OF DERMATITIS DUE TO NUTRITIONAL DEFICIENCIES TO DRIVE MARKET
TABLE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DERMATOLOGIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 PAIN
7.4.1 RISING DEMAND FOR ANTI-INFLAMMATORY DRUGS AND OPIOIDS TO DRIVE MARKET
TABLE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PAIN, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 ORTHOPEDIC DISEASES
7.5.1 GROWING PREVALENCE OF OSTEOARTHRITIS DUE TO INCREASING OBESITY IN PETS TO DRIVE MARKET
TABLE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
7.6 BEHAVIORAL DISORDERS
7.6.1 INCREASING AWARENESS AMONG PET OWNERS FOR APPROPRIATE PET BEHAVIOR TO SUPPORT MARKET GROWTH
TABLE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
7.7 OTHER INDICATIONS
TABLE 32 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
TABLE 33 ROUTES OF ADMINISTRATION FOR KEY COMPANION ANIMAL PHARMACEUTICALS
TABLE 34 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
8.2 ORAL ADMINISTRATION
8.2.1 ABILITY TO TREAT A WIDE RANGE OF DISEASES AND AFFORDABILITY OF MEDICATION TO DRIVE DEMAND
TABLE 35 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 INJECTABLE ADMINISTRATION
8.3.1 ADVANTAGES OF COMPLETE ABSORPTION AND BIOAVAILABILITY TO FUEL MARKET
TABLE 36 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INJECTABLE ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 TOPICAL ADMINISTRATION
8.4.1 TEMPORARY EFFECTS OF TOPICAL DRUGS COMPARED TO ORAL AND PARENTERAL DRUGS TO RESTRAIN MARKET
TABLE 37 COMPANION ANIMAL PHARMACEUTICAL MARKET FOR TOPICAL ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
9 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE
9.1 INTRODUCTION
TABLE 38 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
9.2 DOGS
9.2.1 RISING PET DOG POPULATION WORLDWIDE TO DRIVE MARKET
FIGURE 36 GROWING PET DOG POPULATION IN INDIA (MILLION)
FIGURE 37 POPULATION OF PET DOGS GLOBALLY (MILLION)
TABLE 39 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 CATS
9.3.1 INCREASING R&D ACTIVITIES ON FELINE HEALTH TO DRIVE MARKET
TABLE 40 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 HORSES
9.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
TABLE 41 HORSE POPULATION, BY REGION, 2016–2020 (MILLION)
TABLE 42 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY, 2020–2027 (USD MILLION)
9.5 OTHER COMPANION ANIMALS
TABLE 43 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2020–2027 (USD MILLION)
10 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL
10.1 INTRODUCTION
TABLE 44 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
10.2 VETERINARY HOSPITALS
10.2.1 GROWING FOCUS ON HEALTHCARE AND COMPANION ANIMAL DIAGNOSTIC SERVICES TO DRIVE MARKET
TABLE 45 VETERINARY VISIT EXPENSES FOR CATS AND DOGS (US)
TABLE 46 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
10.3 VETERINARY CLINICS
10.3.1 RISING NUMBER OF PRIVATE CLINICAL PRACTICES TO DRIVE MARKET
TABLE 47 NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY (2019 VS. 2021)
TABLE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
10.4 RETAIL PHARMACIES
10.4.1 ACCESSIBILITY OF PHARMACEUTICALS THROUGH PRESCRIPTIONS AND OTC MEDICATION TO SUPPORT MARKET GROWTH
TABLE 49 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020–2027 (USD MILLION)
11 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 50 COMPANION ANIMAL POPULATION, BY COUNTRY, 2022 (THOUSAND)
FIGURE 38 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT
TABLE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 39 EXPECTED GROWTH FOR NUMBER OF VETERINARIANS IN NORTH AMERICA (2012 VS. 2030)
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 40 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT
TABLE 52 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 54 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 56 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 57 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.2.2 US
11.2.2.1 Rising pet expenditure to fuel market
FIGURE 41 US: POPULATION OF DOGS, 2012–2020 (MILLION)
FIGURE 42 US: EXPENDITURE ON VET VISITS, 2013–2020
TABLE 58 US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2019–2021
TABLE 59 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 60 US: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 61 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 62 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 63 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increasing pet ownership rates to drive demand for vaccines
TABLE 64 CANADA: COMPANION ANIMAL POPULATION, 2016–2020 (MILLION)
TABLE 65 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 66 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 68 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 69 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 70 EUROPE: COMPANION ANIMAL POPULATION, 2021 (MILLION)
TABLE 71 EUROPE: NUMBER OF VETERINARIANS, 2014–2020
11.3.1 EUROPE: RECESSION IMPACT
TABLE 72 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 73 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 74 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 76 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 77 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 Rising focus on animal health due to increasing vet practices to drive market
TABLE 78 GERMANY: COMPANION ANIMAL POPULATION, 2016–2021 (MILLION)
TABLE 79 GERMANY: NUMBER OF VETERINARIANS, 2015 VS. 2020
TABLE 80 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 81 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 82 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 83 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 84 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.3 UK
11.3.3.1 Availability of animal health insurance policies to fuel market for pharmaceuticals
TABLE 85 UK: COMPANION ANIMAL POPULATION, 2017–2020 (MILLION)
TABLE 86 UK: NUMBER OF VETERINARIANS, 2016 VS. 2020
TABLE 87 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 88 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 89 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 90 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 91 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Rising prevalence of infectious diseases to drive demand for animal health products
TABLE 92 FRANCE: COMPANION ANIMAL POPULATION, 2010–2021 (MILLION)
TABLE 93 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 94 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 95 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 96 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 97 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing adoption rates of dogs and cats to fuel market
TABLE 98 SPAIN: COMPANION ANIMAL POPULATION, 2016–2021 (MILLION)
TABLE 99 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 100 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 101 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 102 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 103 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.6 ITALY
11.3.6.1 Lucrative animal and pet health sectors to drive market growth
TABLE 104 ITALY: PET POPULATION, 2017–2021 (MILLION)
TABLE 105 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 106 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 107 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 108 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 109 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 110 REST OF EUROPE: COMPANION ANIMAL OWNERSHIP, 2018 (MILLION)
TABLE 111 REST OF EUROPE: NUMBER OF VETERINARIANS AND PARAVETERINARIANS, 2019 VS. 2020
TABLE 112 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 113 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 114 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 115 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 116 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 43 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT
TABLE 117 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 118 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 119 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 120 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 121 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 122 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Rising number of zoonotic & infectious diseases in animals to drive market
FIGURE 44 CHINA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
TABLE 123 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 124 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 126 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 127 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 Rising demand for imported breeds to support market growth
TABLE 128 JAPAN: DOMESTICATED DOG AND CAT POPULATION, 2012–2020 (THOUSAND)
TABLE 129 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 130 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 132 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 133 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Rising focus on pet care due to a large population of domesticated animals to drive market
FIGURE 45 INDIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
TABLE 134 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 135 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 136 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 137 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 138 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Pet care initiatives for street dogs and cats to fuel market for animal care products
TABLE 139 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 140 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 141 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 142 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 143 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.6 AUSTRALIA
11.4.6.1 Growing awareness of parasitic infections to drive demand for parasiticides
FIGURE 46 AUSTRALIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
TABLE 144 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 145 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 147 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 148 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 149 REST OF ASIA PACIFIC: NUMBER OF VETERINARIANS, 2012?2021
TABLE 150 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 151 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 152 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 153 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 154 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 GROWING POOL OF SKILLED VETERINARIANS OWING TO RISING PET POPULATION TO DRIVE MARKET
TABLE 155 NUMBER OF VETERINARIANS AND VETERINARY PARA-PROFESSIONALS IN LATIN AMERICA (2016 VS. 2019)
11.5.2 LATIN AMERICA: RECESSION IMPACT
TABLE 156 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 157 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 158 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 159 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 160 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 EMERGING MARKET FOR ANIMAL HEALTHCARE PRACTISES TO SUPPORT UPTAKE
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 161 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 162 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 163 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 164 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 165 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
FIGURE 47 KEY PLAYER STRATEGIES ADOPTED BY MARKET PLAYERS (2019–2022)
12.2 REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS
FIGURE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET: REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2017–2021)
12.3 MARKET SHARE ANALYSIS
FIGURE 49 COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER (2021)
12.4 COMPANY EVALUATION QUADRANT
12.4.1 STARS
12.4.2 EMERGING LEADERS
12.4.3 PERVASIVE PLAYERS
12.4.4 PARTICIPANTS
FIGURE 50 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPANY EVALUATION QUADRANT (2021)
12.5 EVALUATION QUADRANT FOR STARTUPS/SMES
12.5.1 PROGRESSIVE COMPANIES
12.5.2 DYNAMIC COMPANIES
12.5.3 STARTING BLOCKS
12.5.4 RESPONSIVE COMPANIES
FIGURE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET: STARTUPS/SME EVALUATION QUADRANT (2021)
12.6 COMPETITIVE BENCHMARKING
TABLE 166 COMPANION ANIMAL PHARMACEUTICALS MARKET: INDICATION PORTFOLIO ANALYSIS:
TABLE 167 COMPANION ANIMAL PHARMACEUTICALS MARKET: ROUTE OF ADMINISTRATION PORTFOLIO ANALYSIS
TABLE 168 COMPANION ANIMAL PHARMACEUTICALS MARKET: ANIMAL TYPE PORTFOLIO ANALYSIS
TABLE 169 COMPANION ANIMAL PHARMACEUTICALS MARKET: DISTRIBUTION CHANNEL PORTFOLIO ANALYSIS
12.7 COMPANY GEOGRAPHIC FOOTPRINT
TABLE 170 COMPANION ANIMAL PHARMACEUTICALS MARKET: REGIONAL REVENUE MIX
12.8 COMPETITIVE SITUATION AND TRENDS
12.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 171 PRODUCT LAUNCHES & APPROVALS
12.8.2 DEALS
TABLE 172 DEALS
12.8.3 OTHER DEVELOPMENTS
TABLE 173 OTHER DEVELOPMENTS
13 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1 KEY PLAYERS
13.1.1 ZOETIS INC.
TABLE 174 ZOETIS INC.: BUSINESS OVERVIEW
FIGURE 52 ZOETIS: COMPANY SNAPSHOT (2021)
13.1.2 MERCK & CO., INC.
TABLE 175 MERCK & CO., INC.: BUSINESS OVERVIEW
FIGURE 53 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)
13.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
TABLE 176 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
FIGURE 54 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2021)
13.1.4 ELANCO ANIMAL HEALTH INCORPORATED
TABLE 177 ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW
FIGURE 55 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2021)
13.1.5 VIRBAC
TABLE 178 VIRBAC: BUSINESS OVERVIEW
FIGURE 56 VIRBAC: COMPANY SNAPSHOT (2021)
13.1.6 DECHRA PHARMACEUTICALS PLC
TABLE 179 DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW
FIGURE 57 DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2021)
13.1.7 VETOQUINOL
TABLE 180 VETOQUINOL: BUSINESS OVERVIEW
FIGURE 58 VETOQUINOL: COMPANY SNAPSHOT (2021)
13.1.8 NEOGEN CORPORATION
TABLE 181 NEOGEN CORPORATION: BUSINESS OVERVIEW
FIGURE 59 NEOGEN CORPORATION: COMPANY SNAPSHOT (2021)
13.1.9 ORION GROUP
TABLE 182 ORION GROUP: BUSINESS OVERVIEW
FIGURE 60 ORION GROUP: COMPANY SNAPSHOT (2021)
13.1.10 ECO ANIMAL HEALTH GROUP PLC
TABLE 183 ECO ANIMAL HEALTH GROUP PLC: BUSINESS OVERVIEW
FIGURE 61 ECO ANIMAL HEALTH GROUP PLC: COMPANY SNAPSHOT (2021)
13.2 OTHER PLAYERS
13.2.1 ZENEX ANIMAL HEALTH INDIA PRIVATE LIMITED
13.2.2 NORBROOK
13.2.3 CHANELLE PHARMA
13.2.4 HIPRA
13.2.5 CEVA SANT? ANIMALE
13.2.6 TIANJIN RINPU BIO-TECHNOLOGY CO., LTD.
13.2.7 KYORITSU SEIYAKU
13.2.8 ENDOVAC ANIMAL HEALTH
13.2.9 INDIAN IMMUNOLOGICALS LTD.
13.2.10 ASHISH LIFE SCIENCE PVT. LTD.
13.2.11 PHARMA PVT. LTD.
13.2.12 BIOGENESIS BAGO S.A.
13.2.13 INTAS PHARMACEUTICALS
13.2.14 BRILLIANT BIOPHARMA
13.2.15 VETINDIA PHARMACEUTICALS LIMITED
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX
14.1 INDUSTRY EXPERT INSIGHTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 CUSTOMIZATION OPTIONS
14.5 RELATED REPORTS
14.6 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.2.2 MARKETS COVERED
FIGURE 1 COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED
1.3 CURRENCY CONSIDERED
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 REFINEMENTS IN SEGMENTS OF GLOBAL MARKET
1.6.2 UPDATED FINANCIAL INFORMATION/PRODUCT PORTFOLIOS OF PLAYERS
1.6.3 UPDATED MARKET DEVELOPMENTS OF PROFILED PLAYERS
1.6.4 ADDITION OF RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
2.1.2.4 Breakdown of primaries
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: ZOETIS INC.
FIGURE 6 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY-SIDE ANALYSIS
FIGURE 7 MARKET ANALYSIS APPROACH
FIGURE 8 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET APPROACH
FIGURE 9 TOP-DOWN APPROACH
FIGURE 10 CAGR PROJECTIONS
FIGURE 11 COMPANION ANIMAL PHARMACEUTICALS MARKET (2022–2027): IMPACT ANALYSIS ON DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.3 DATA TRIANGULATION APPROACH
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
2.7 LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 IMPACT OF RECESSION
3 EXECUTIVE SUMMARY
FIGURE 13 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 14 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2027 (USD MILLION)
FIGURE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2022 VS. 2027 (USD MILLION)
FIGURE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHICAL SNAPSHOT
4 PREMIUM INSIGHTS
4.1 COMPANION ANIMAL PHARMACEUTICALS MARKET OVERVIEW
FIGURE 18 INCREASING PREVALENCE OF ZOONOTIC DISEASES AND RISING PET OWNERSHIP RATES WORLDWIDE TO DRIVE MARKET
4.2 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION AND COUNTRY (2021)
FIGURE 19 INFECTIOUS DISEASES SEGMENT IN GERMANY ACCOUNTED FOR LARGEST SHARE IN 2021
4.3 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 CHINA & INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (2022–2027)
FIGURE 21 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING FORECAST PERIOD
4.5 COMPANION ANIMAL PHARMACEUTICALS MARKET: DEVELOPED VS. EMERGING MARKETS
FIGURE 22 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 COMPANION ANIMAL PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 MARKET DRIVERS
5.2.1.1 Rising prevalence of zoonotic diseases
TABLE 2 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2013–2019)
5.2.1.2 Rising demand for pet insurance due to growing animal health expenditure
TABLE 3 US: AVERAGE PREMIUM RATES (2019–2021)
FIGURE 24 CANADA: AVERAGE ANNUAL PREMIUMS (2017–2021)
TABLE 4 NORTH AMERICA: PET HEALTH INSURANCE MARKET, 2012–2021 (USD MILLION)
5.2.1.3 Increasing R&D investments for animal healthcare
5.2.1.4 Rising awareness initiatives by government agencies and animal welfare organizations
5.2.1.5 High pet ownership rates worldwide
TABLE 5 PET POPULATION, BY ANIMAL, 2014–2020 (MILLION)
TABLE 6 MARKET DRIVERS: IMPACT ANALYSIS
5.2.2 MARKET RESTRAINTS
5.2.2.1 Rising pet care costs
FIGURE 25 US: PET INDUSTRY EXPENDITURE, 2010–2020
5.2.2.2 Limited number of novel pharmaceuticals for veterinary care
5.2.2.3 High cost of vaccines and complexities associated with storage
5.2.2.4 Growing resistance to antimicrobials and antibiotics
TABLE 7 MARKET RESTRAINTS: IMPACT ANALYSIS
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Lucrative growth opportunities in emerging markets
5.2.3.2 Growing prevalence of chronic animal diseases
5.2.3.3 Rising technological advancements in vaccine manufacturing
TABLE 8 MARKET OPPORTUNITIES: IMPACT ANALYSIS
5.2.4 MARKET CHALLENGES
5.2.4.1 Stringent regulatory approval process for pharmaceuticals
5.2.4.2 Limited awareness of vaccine coverage
5.2.4.3 Misdiagnosis due to diversity of parasites
5.2.4.4 Low animal healthcare expenditure in emerging markets
TABLE 9 MARKET CHALLENGES: IMPACT ANALYSIS
6 INDUSTRY INSIGHTS
6.1 INTRODUCTION
6.2 INDUSTRY TRENDS
6.2.1 RISING ACQUISITIONS OF SMALLER COMPANIES BY GLOBAL PLAYERS
TABLE 10 COMPANION ANIMAL PHARMACEUTICALS MARKET: MAJOR ACQUISITIONS (2017–2022)
6.2.2 INCREASING PRODUCT INNOVATIONS FOR ANIMAL HEALTHCARE
TABLE 11 INNOVATIVE COMPANION ANIMAL PHARMACEUTICAL TRENDS
6.2.3 EXPANDING VETERINARY BUSINESSES WORLDWIDE
6.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 12 PORTER’S FIVE FORCES ANALYSIS
6.3.1 THREAT OF NEW ENTRANTS
6.3.2 THREAT OF SUBSTITUTES
6.3.3 BARGAINING POWER OF SUPPLIERS
6.3.4 BARGAINING POWER OF BUYERS
6.3.5 INTENSITY OF COMPETITIVE RIVALRY
6.4 REGULATORY ANALYSIS
FIGURE 26 COMPANION ANIMAL PHARMACEUTICAL MARKET: DEVELOPMENT AND APPROVAL PROCESS FOR PRODUCTS
TABLE 13 US: RECENT DEVELOPMENTS IN REGULATIONS FOR VETERINARY DRUGS
FIGURE 27 COMPANION ANIMAL PHARMACEUTICAL MARKET: PRODUCT APPROVAL PROCESS IN EUROPE
6.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.4.1.1 US
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.4.1.2 Europe
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.4.1.3 Rest of the World
TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.5 VALUE CHAIN ANALYSIS
FIGURE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS
6.6 SUPPLY CHAIN ANALYSIS
FIGURE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS
6.7 ECOSYSTEM ANALYSIS
6.7.1 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS
FIGURE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS
6.8 PATENT ANALYSIS
6.8.1 COMPANION ANIMAL PHARMACEUTICALS MARKET: PATENT ANALYSIS TRENDS
FIGURE 31 PATENT PUBLICATION TRENDS (JANUARY 2013–DECEMBER 2022)
6.8.2 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICALS
FIGURE 32 COMPANION ANIMAL PHARMACEUTICALS MARKET: TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR PATENTS (2017–2022)
6.8.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR COMPANION ANIMAL PHARMACEUTICALS
FIGURE 33 COMPANION ANIMAL PHARMACEUTICAL MARKET: TOP APPLICANT COUNTRIES FOR PATENTS (2017–2022)
6.9 PRICING ANALYSIS
TABLE 17 AVERAGE SELLING PRICES OF COMPANION ANIMAL PHARMACEUTICALS BY APPLICATION (USD)
6.10 KEY CONFERENCES AND EVENTS FROM 2023 TO 2024
TABLE 18 COMPANION ANIMAL PHARMACEUTICALS MARKET: CONFERENCES AND EVENTS
6.11 KEY STAKEHOLDERS & BUYING CRITERIA
6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 34 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS
TABLE 19 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS
FIGURE 35 BUYING CRITERIA
TABLE 20 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS
6.12 TRADE ANALYSIS
7 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION
7.1 INTRODUCTION
TABLE 21 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
7.2 INFECTIOUS DISEASES
TABLE 22 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 23 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 PARASITICIDES
7.2.1.1 Growing regulatory guidelines to control parasite-related diseases to fuel market
TABLE 24 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.2 VACCINES
7.2.2.1 Growing awareness among pet owners for canine & feline vaccines to drive market
TABLE 25 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 ANTIBIOTICS AND ANTIMICROBIALS
7.2.3.1 Effective prevention for clinical and subclinical diseases in companion animals to fuel uptake
TABLE 26 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS AND ANTIMICROBIALS, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.4 OTHERS
TABLE 27 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 DERMATOLOGIC DISEASES
7.3.1 RISING CASES OF DERMATITIS DUE TO NUTRITIONAL DEFICIENCIES TO DRIVE MARKET
TABLE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DERMATOLOGIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 PAIN
7.4.1 RISING DEMAND FOR ANTI-INFLAMMATORY DRUGS AND OPIOIDS TO DRIVE MARKET
TABLE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PAIN, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 ORTHOPEDIC DISEASES
7.5.1 GROWING PREVALENCE OF OSTEOARTHRITIS DUE TO INCREASING OBESITY IN PETS TO DRIVE MARKET
TABLE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
7.6 BEHAVIORAL DISORDERS
7.6.1 INCREASING AWARENESS AMONG PET OWNERS FOR APPROPRIATE PET BEHAVIOR TO SUPPORT MARKET GROWTH
TABLE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION)
7.7 OTHER INDICATIONS
TABLE 32 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION
8.1 INTRODUCTION
TABLE 33 ROUTES OF ADMINISTRATION FOR KEY COMPANION ANIMAL PHARMACEUTICALS
TABLE 34 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
8.2 ORAL ADMINISTRATION
8.2.1 ABILITY TO TREAT A WIDE RANGE OF DISEASES AND AFFORDABILITY OF MEDICATION TO DRIVE DEMAND
TABLE 35 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 INJECTABLE ADMINISTRATION
8.3.1 ADVANTAGES OF COMPLETE ABSORPTION AND BIOAVAILABILITY TO FUEL MARKET
TABLE 36 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INJECTABLE ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 TOPICAL ADMINISTRATION
8.4.1 TEMPORARY EFFECTS OF TOPICAL DRUGS COMPARED TO ORAL AND PARENTERAL DRUGS TO RESTRAIN MARKET
TABLE 37 COMPANION ANIMAL PHARMACEUTICAL MARKET FOR TOPICAL ADMINISTRATION, BY COUNTRY, 2020–2027 (USD MILLION)
9 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE
9.1 INTRODUCTION
TABLE 38 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
9.2 DOGS
9.2.1 RISING PET DOG POPULATION WORLDWIDE TO DRIVE MARKET
FIGURE 36 GROWING PET DOG POPULATION IN INDIA (MILLION)
FIGURE 37 POPULATION OF PET DOGS GLOBALLY (MILLION)
TABLE 39 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 CATS
9.3.1 INCREASING R&D ACTIVITIES ON FELINE HEALTH TO DRIVE MARKET
TABLE 40 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 HORSES
9.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
TABLE 41 HORSE POPULATION, BY REGION, 2016–2020 (MILLION)
TABLE 42 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY, 2020–2027 (USD MILLION)
9.5 OTHER COMPANION ANIMALS
TABLE 43 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2020–2027 (USD MILLION)
10 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL
10.1 INTRODUCTION
TABLE 44 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
10.2 VETERINARY HOSPITALS
10.2.1 GROWING FOCUS ON HEALTHCARE AND COMPANION ANIMAL DIAGNOSTIC SERVICES TO DRIVE MARKET
TABLE 45 VETERINARY VISIT EXPENSES FOR CATS AND DOGS (US)
TABLE 46 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
10.3 VETERINARY CLINICS
10.3.1 RISING NUMBER OF PRIVATE CLINICAL PRACTICES TO DRIVE MARKET
TABLE 47 NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY (2019 VS. 2021)
TABLE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2020–2027 (USD MILLION)
10.4 RETAIL PHARMACIES
10.4.1 ACCESSIBILITY OF PHARMACEUTICALS THROUGH PRESCRIPTIONS AND OTC MEDICATION TO SUPPORT MARKET GROWTH
TABLE 49 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020–2027 (USD MILLION)
11 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 50 COMPANION ANIMAL POPULATION, BY COUNTRY, 2022 (THOUSAND)
FIGURE 38 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT
TABLE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 39 EXPECTED GROWTH FOR NUMBER OF VETERINARIANS IN NORTH AMERICA (2012 VS. 2030)
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 40 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT
TABLE 52 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 54 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 56 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 57 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.2.2 US
11.2.2.1 Rising pet expenditure to fuel market
FIGURE 41 US: POPULATION OF DOGS, 2012–2020 (MILLION)
FIGURE 42 US: EXPENDITURE ON VET VISITS, 2013–2020
TABLE 58 US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2019–2021
TABLE 59 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 60 US: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 61 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 62 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 63 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increasing pet ownership rates to drive demand for vaccines
TABLE 64 CANADA: COMPANION ANIMAL POPULATION, 2016–2020 (MILLION)
TABLE 65 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 66 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 67 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 68 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 69 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 70 EUROPE: COMPANION ANIMAL POPULATION, 2021 (MILLION)
TABLE 71 EUROPE: NUMBER OF VETERINARIANS, 2014–2020
11.3.1 EUROPE: RECESSION IMPACT
TABLE 72 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 73 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 74 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 76 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 77 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 Rising focus on animal health due to increasing vet practices to drive market
TABLE 78 GERMANY: COMPANION ANIMAL POPULATION, 2016–2021 (MILLION)
TABLE 79 GERMANY: NUMBER OF VETERINARIANS, 2015 VS. 2020
TABLE 80 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 81 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 82 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 83 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 84 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.3 UK
11.3.3.1 Availability of animal health insurance policies to fuel market for pharmaceuticals
TABLE 85 UK: COMPANION ANIMAL POPULATION, 2017–2020 (MILLION)
TABLE 86 UK: NUMBER OF VETERINARIANS, 2016 VS. 2020
TABLE 87 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 88 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 89 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 90 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 91 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Rising prevalence of infectious diseases to drive demand for animal health products
TABLE 92 FRANCE: COMPANION ANIMAL POPULATION, 2010–2021 (MILLION)
TABLE 93 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 94 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 95 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 96 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 97 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Increasing adoption rates of dogs and cats to fuel market
TABLE 98 SPAIN: COMPANION ANIMAL POPULATION, 2016–2021 (MILLION)
TABLE 99 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 100 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 101 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 102 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 103 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.6 ITALY
11.3.6.1 Lucrative animal and pet health sectors to drive market growth
TABLE 104 ITALY: PET POPULATION, 2017–2021 (MILLION)
TABLE 105 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 106 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 107 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 108 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 109 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 110 REST OF EUROPE: COMPANION ANIMAL OWNERSHIP, 2018 (MILLION)
TABLE 111 REST OF EUROPE: NUMBER OF VETERINARIANS AND PARAVETERINARIANS, 2019 VS. 2020
TABLE 112 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 113 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 114 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 115 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 116 REST OF EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 43 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT
TABLE 117 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 118 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 119 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 120 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 121 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 122 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Rising number of zoonotic & infectious diseases in animals to drive market
FIGURE 44 CHINA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
TABLE 123 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 124 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 126 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 127 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 Rising demand for imported breeds to support market growth
TABLE 128 JAPAN: DOMESTICATED DOG AND CAT POPULATION, 2012–2020 (THOUSAND)
TABLE 129 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 130 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 132 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 133 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Rising focus on pet care due to a large population of domesticated animals to drive market
FIGURE 45 INDIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
TABLE 134 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 135 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 136 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 137 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 138 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Pet care initiatives for street dogs and cats to fuel market for animal care products
TABLE 139 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 140 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 141 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 142 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 143 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.6 AUSTRALIA
11.4.6.1 Growing awareness of parasitic infections to drive demand for parasiticides
FIGURE 46 AUSTRALIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION)
TABLE 144 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 145 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 147 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 148 AUSTRALIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 149 REST OF ASIA PACIFIC: NUMBER OF VETERINARIANS, 2012?2021
TABLE 150 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 151 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 152 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 153 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 154 REST OF ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 GROWING POOL OF SKILLED VETERINARIANS OWING TO RISING PET POPULATION TO DRIVE MARKET
TABLE 155 NUMBER OF VETERINARIANS AND VETERINARY PARA-PROFESSIONALS IN LATIN AMERICA (2016 VS. 2019)
11.5.2 LATIN AMERICA: RECESSION IMPACT
TABLE 156 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 157 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 158 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 159 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 160 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 EMERGING MARKET FOR ANIMAL HEALTHCARE PRACTISES TO SUPPORT UPTAKE
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 161 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2020–2027 (USD MILLION)
TABLE 162 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 163 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION)
TABLE 164 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2020–2027 (USD MILLION)
TABLE 165 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
FIGURE 47 KEY PLAYER STRATEGIES ADOPTED BY MARKET PLAYERS (2019–2022)
12.2 REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS
FIGURE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET: REVENUE SHARE ANALYSIS OF TOP FIVE PLAYERS (2017–2021)
12.3 MARKET SHARE ANALYSIS
FIGURE 49 COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER (2021)
12.4 COMPANY EVALUATION QUADRANT
12.4.1 STARS
12.4.2 EMERGING LEADERS
12.4.3 PERVASIVE PLAYERS
12.4.4 PARTICIPANTS
FIGURE 50 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPANY EVALUATION QUADRANT (2021)
12.5 EVALUATION QUADRANT FOR STARTUPS/SMES
12.5.1 PROGRESSIVE COMPANIES
12.5.2 DYNAMIC COMPANIES
12.5.3 STARTING BLOCKS
12.5.4 RESPONSIVE COMPANIES
FIGURE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET: STARTUPS/SME EVALUATION QUADRANT (2021)
12.6 COMPETITIVE BENCHMARKING
TABLE 166 COMPANION ANIMAL PHARMACEUTICALS MARKET: INDICATION PORTFOLIO ANALYSIS:
TABLE 167 COMPANION ANIMAL PHARMACEUTICALS MARKET: ROUTE OF ADMINISTRATION PORTFOLIO ANALYSIS
TABLE 168 COMPANION ANIMAL PHARMACEUTICALS MARKET: ANIMAL TYPE PORTFOLIO ANALYSIS
TABLE 169 COMPANION ANIMAL PHARMACEUTICALS MARKET: DISTRIBUTION CHANNEL PORTFOLIO ANALYSIS
12.7 COMPANY GEOGRAPHIC FOOTPRINT
TABLE 170 COMPANION ANIMAL PHARMACEUTICALS MARKET: REGIONAL REVENUE MIX
12.8 COMPETITIVE SITUATION AND TRENDS
12.8.1 PRODUCT LAUNCHES & APPROVALS
TABLE 171 PRODUCT LAUNCHES & APPROVALS
12.8.2 DEALS
TABLE 172 DEALS
12.8.3 OTHER DEVELOPMENTS
TABLE 173 OTHER DEVELOPMENTS
13 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1 KEY PLAYERS
13.1.1 ZOETIS INC.
TABLE 174 ZOETIS INC.: BUSINESS OVERVIEW
FIGURE 52 ZOETIS: COMPANY SNAPSHOT (2021)
13.1.2 MERCK & CO., INC.
TABLE 175 MERCK & CO., INC.: BUSINESS OVERVIEW
FIGURE 53 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)
13.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
TABLE 176 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
FIGURE 54 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2021)
13.1.4 ELANCO ANIMAL HEALTH INCORPORATED
TABLE 177 ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW
FIGURE 55 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2021)
13.1.5 VIRBAC
TABLE 178 VIRBAC: BUSINESS OVERVIEW
FIGURE 56 VIRBAC: COMPANY SNAPSHOT (2021)
13.1.6 DECHRA PHARMACEUTICALS PLC
TABLE 179 DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW
FIGURE 57 DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2021)
13.1.7 VETOQUINOL
TABLE 180 VETOQUINOL: BUSINESS OVERVIEW
FIGURE 58 VETOQUINOL: COMPANY SNAPSHOT (2021)
13.1.8 NEOGEN CORPORATION
TABLE 181 NEOGEN CORPORATION: BUSINESS OVERVIEW
FIGURE 59 NEOGEN CORPORATION: COMPANY SNAPSHOT (2021)
13.1.9 ORION GROUP
TABLE 182 ORION GROUP: BUSINESS OVERVIEW
FIGURE 60 ORION GROUP: COMPANY SNAPSHOT (2021)
13.1.10 ECO ANIMAL HEALTH GROUP PLC
TABLE 183 ECO ANIMAL HEALTH GROUP PLC: BUSINESS OVERVIEW
FIGURE 61 ECO ANIMAL HEALTH GROUP PLC: COMPANY SNAPSHOT (2021)
13.2 OTHER PLAYERS
13.2.1 ZENEX ANIMAL HEALTH INDIA PRIVATE LIMITED
13.2.2 NORBROOK
13.2.3 CHANELLE PHARMA
13.2.4 HIPRA
13.2.5 CEVA SANT? ANIMALE
13.2.6 TIANJIN RINPU BIO-TECHNOLOGY CO., LTD.
13.2.7 KYORITSU SEIYAKU
13.2.8 ENDOVAC ANIMAL HEALTH
13.2.9 INDIAN IMMUNOLOGICALS LTD.
13.2.10 ASHISH LIFE SCIENCE PVT. LTD.
13.2.11 PHARMA PVT. LTD.
13.2.12 BIOGENESIS BAGO S.A.
13.2.13 INTAS PHARMACEUTICALS
13.2.14 BRILLIANT BIOPHARMA
13.2.15 VETINDIA PHARMACEUTICALS LIMITED
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX
14.1 INDUSTRY EXPERT INSIGHTS
14.2 DISCUSSION GUIDE
14.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4 CUSTOMIZATION OPTIONS
14.5 RELATED REPORTS
14.6 AUTHOR DETAILS
